Literature DB >> 24949836

The chorioretinal damage caused by different half parameters of photodynamic therapy in rabbits.

Lan-Hsin Chuang1, Yih-Shiou Hwang, Nan-Kai Wang, Yen-Po Chen, Laura Liu, Ling Yeung, Kuan-Jen Chen, Tun-Lu Chen, Wei-Chi Wu, Chi-Chun Lai.   

Abstract

PURPOSE: To compare the chorioretinal tissue response after different half-strength parameters of photodynamic therapy (PDT) in rabbits.
METHODS: The study included 4 groups, and each group contained 4 animals. The full dose served as the control group: verteporfin (4 mg/kg) with 600 mW/cm(2) irradiance from a diode laser at 689 nm applied to the retina for 8 s. One parameter was changed to half-strength in the other 3 groups. The HLaser group received half-strength laser irradiance. The HTime group was exposed to photosensitization for half the time, and the HDose group received half the drug dose. Six laser spots were generated in each of the eyes of every rabbit and documented graphically. The lesions were examined on days 1, 7, and 42 after PDT treatment using color fundus imaging, fluorescein angiography (FA), and histopathology analysis.
RESULTS: PDT treatment in rabbits caused chorioretinal damage in all 4 groups. FA on day 1 showed that the use of half the laser irradiance, half the drug dose, or half the photosensitizing time tended to decrease the damage to the chorioretinal tissue in terms of the number of occlusions and the area of occlusion, but only the results from half the laser irradiance were significantly different. In addition, the HLaser and HDose groups showed significantly less apoptosis by TUNEL staining on day 1.
CONCLUSIONS: Among these PDT parameters, decreasing the laser irradiance by half showed the greatest decrease in chorioretinal damage in an experimental animal model.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24949836      PMCID: PMC4186804          DOI: 10.1089/jop.2013.0219

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  36 in total

1.  Photodynamic therapy in chronic central serous chorioretinopathy.

Authors:  M Battaglia Parodi; S Da Pozzo; G Ravalico
Journal:  Retina       Date:  2003-04       Impact factor: 4.256

Review 2.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

3.  Photodynamic effects on choroidal neovascularization and physiological choroid.

Authors:  Ursula Schmidt-Erfurth; Stephan Michels; Irene Barbazetto; Horst Laqua
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-03       Impact factor: 4.799

4.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

5.  Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3.

Authors:  Jennifer J Arnold; Kevin J Blinder; Neil M Bressler; Susan B Bressler; Amy Burdan; Laurie Haynes; Jennifer I Lim; Joan W Miller; Michael J Potter; Al Reaves; Philip J Rosenfeld; Michel Sickenberg; Jason S Slakter; Gisèle Soubrane; H Andrew Strong; Michael Stur
Journal:  Am J Ophthalmol       Date:  2004-04       Impact factor: 5.258

6.  Laser photocoagulation of indocyanine green angiographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathy.

Authors:  Kazuaki Nishijima; Masayo Takahashi; Joh Akita; Hideto Katsuta; Mai Tanemura; Hiroko Aikawa; Michiko Mandai; Hitoshi Takagi; Junichi Kiryu; Yoshihito Honda
Journal:  Am J Ophthalmol       Date:  2004-04       Impact factor: 5.258

7.  Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1.

Authors:  Keven J Blinder; Shannon Bradley; Neil M Bressler; Susan B Bressler; Guy Donati; Yong Hao; Colin Ma; Ugo Menchini; Joan Miller; Michael J Potter; Constantin Pournaras; Al Reaves; Philip J Rosenfeld; H Andrew Strong; Michael Stur; Xiang Yao Su; Gianni Virgili
Journal:  Am J Ophthalmol       Date:  2003-09       Impact factor: 5.258

8.  Influence of photodynamic therapy in choroidal neovascularization on focal retinal function assessed with the multifocal electroretinogram and perimetry.

Authors:  Anja M Palmowski; Reiner Allgayer; Bernhild Heinemann-Vernaleken; Klaus W Ruprecht
Journal:  Ophthalmology       Date:  2002-10       Impact factor: 12.079

9.  Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study.

Authors:  Lawrence A Yannuzzi; Jason S Slakter; Nicole E Gross; Richard F Spaide; Danielle L L Costa; Sheau J Huang; James M Klancnik; Alexander Aizman
Journal:  Retina       Date:  2003-06       Impact factor: 4.256

10.  Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes.

Authors:  Ursula Schlötzer-Schrehardt; Arne Viestenz; Gottfried O H Naumann; Horst Laqua; S Michels; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-08-27       Impact factor: 3.117

View more
  2 in total

1.  Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy.

Authors:  Ayako Yasui; Manabu Yamamoto; Kumiko Hirayama; Kunihiko Shiraki; Dirk Theisen-Kunde; Ralf Brinkmann; Yoko Miura; Takeya Kohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-06       Impact factor: 3.117

2.  Rabbit model of ocular indirect photodynamic therapy using a retinoblastoma xenograft.

Authors:  Jonathan W Kim; Bradley Jacobsen; Emily Zolfaghari; Angela Ferrario; Patricia Chevez-Barrios; Jesse L Berry; Diana K Lee; Grecia Rico; Ingy Madi; Narsing Rao; Kevin Stachelek; Lei-Chi Wang; Charles Gomer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-10-02       Impact factor: 3.117

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.